Buprenorphine for Cancer Pain

• Status: Recruiting
• Trial end date: 2024-10-10
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate patients on both buprenorphine and full agonist opioids (FAO) to assess for withdrawal symptoms. Patients will be evaluated by clinicians and using validated tools to assess for pain and withdrawal. At the same time, patients will use a CPM Rx application on their phone to track medication use.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fox Chase Cancer Center
• Treatments: Buprenorphine

Criteria

1. Age greater than or equal to 18 years

2. English speaking and able to understand and sign informed consent and HIPAA consent document.

3. The patient will have pain from any cause with a pain level greater than or equal to 4 on a visual analog scale.

4. The patient will be able to complete study assessments including use of the CPM app (requires Smart Phone)

5. Patients who may become pregnant are using adequate contraceptives.

6. Patient is on the combination of buprenorphine and full agonist opioid > 30 mg oral morphine equivalent or being started on both buprenorphine and full agonist opioid >30 mg oral morphine equivalent at the time of enrollment